Evidence map›Paper›PMID 26123575›Full record

ArticleRetrovirology2015

Disease progression despite protective HLA expression in an HIV-infected transmission pair.

Jacqui Brener, Astrid Gall, Rebecca Batorsky, Lynn Riddell, Soren Buus, Ellen Leitman, Paul Kellam, Todd Allen, Philip Goulder, Philippa C Matthews

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. CD8Frontiers in microbiology · 2021
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jacqui BrenerDepartment of Paediatrics, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, OX1 3SY, UK. jacqui.brener@wolfson.ox.ac.uk.
Astrid GallWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK. ag8@sanger.ac.uk.
Rebecca BatorskyRagon Institute of MGH, MIT and Harvard, Boston, MA, USA. rbatorsky@mgh.harvard.edu.
Lynn RiddellIntegrated Sexual Health Services, Northamptonshire Healthcare NHS Foundation Trust, Northampton General Hospital, Cliftonville, Northampton, NN1 5BD, UK. joanne.whitcombe@nhft.nhs.uk.
Soren BuusDepartment of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen N, Denmark. sbuus@sund.ku.dk.
Ellen LeitmanDepartment of Paediatrics, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, OX1 3SY, UK. ellen.leitman@st-hughs.ox.ac.uk.
Paul KellamWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK. pk5@sanger.ac.uk.
Todd AllenRagon Institute of MGH, MIT and Harvard, Boston, MA, USA. TALLEN2@mgh.harvard.edu.
Philip GoulderDepartment of Paediatrics, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, OX1 3SY, UK. philip.goulder@paediatrics.ox.ac.uk.
Philippa C MatthewsNuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, OX1 3SY, UK. p.matthews@doctors.org.uk.
Medawar Building for Pathogen Research · GBRagon Institute of MGH, MIT and Harvard · USWellcome Sanger Institute · GBNorthamptonshire Healthcare NHS Foundation Trust · GBUniversity of Copenhagen · DK

Funding

Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan AfriR01AI046995 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2000 to 2014
$6.8M
Medical Research Council G0501777NIAID NIH HHS R01 AI046995Wellcome Trust 104748Wellcome Trust WT 104748MA
6 · The paper itself

Abstract

backgroundThe precise immune responses mediated by HLA class I molecules such as HLA-B*27:05 and HLA-B*57:01 that protect against HIV disease progression remain unclear. We studied a CRF01_AE clade HIV infected donor-recipient transmission pair in which the recipient expressed both HLA-B*27:05 and HLA-B*57:01.

resultsWithin 4.5 years of diagnosis, the recipient had progressed to meet criteria for antiretroviral therapy initiation. We employed ultra-deep sequencing of the full-length virus genome in both donor and recipient as an unbiased approach by which to identify specific viral mutations selected in association with progression. Using a heat map method to highlight differences in the viral sequences between donor and recipient, we demonstrated that the majority of the recipient's mutations outside of Env were within epitopes restricted by HLA-B*27:05 and HLA-B*57:01, including the well-studied Gag epitopes. The donor, who also expressed HLA alleles associated with disease protection, HLA-A*32:01/B*13:02/B*14:01, showed selection of mutations in parallel with disease progression within epitopes restricted by these protective alleles.

conclusionsThese studies of full-length viral sequences in a transmission pair, both of whom expressed protective HLA alleles but nevertheless failed to control viremia, are consistent with previous reports pointing to the critical role of Gag-specific CD8+ T cell responses restricted by protective HLA molecules in maintaining immune control of HIV infection. The transmission of subtype CRF01_AE clade infection may have contributed to accelerated disease progression in this pair as a result of clade-specific sequence differences in immunodominant epitopes.

Indexed as

Disease ProgressionAdultEpitopesFamily CharacteristicsFemalegag Gene Products, Human Immunodeficiency VirusGene ExpressionHIVHIV InfectionsHLA-B27 AntigenHLA-B AntigensHumansMaleMolecular Sequence DataMutation, MissenseSequence Analysis, DNAEpitopesgag Gene Products, Human Immunodeficiency VirusHLA-B*27:05 antigenHLA-B27 AntigenHLA-B*57:01 antigenHLA-B Antigens

Identifiers

PMID26123575
PMCPMC4487201
OpenAlexW1783283619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.